Clinical Trial Record

Return to Clinical Trials

Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.


2011-01-01


2022-07-01


2022-12-01


520

Study Overview

Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with relatively poor survival. Surgery is the first choice for the treatment of patients with early pancreatic cancer. However, the surgical approach and the extent of resection for patients with pancreatic cancer are controversial at present. The investigators optimized the procedure of standard pancreaticoduodenectomy to selective extended dissection (SED), which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor. The investigators retrospectively analyzed the clinicopathological data of patients with pancreatic adenocarcinoma who underwent radical surgery in our center from 2011 to 2020. Patients who underwent standard dissection (SD) were matched 2:1 to those who underwent SED using propensity score matching (PSM). The log-rank test and cox regression model were used to analyze survival data. In addition, statistical analyses were performed for the perioperative complications, postoperative pathology and recurrence pattern.

N/A

  • Carcinoma, Pancreatic Ductal
  • PROCEDURE: Selective extended dissection of pancreaticoduodenectomy
  • Panc-2023129

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2023-01-31  

N/A  

2023-02-09  

2023-02-09  

N/A  

2023-02-13  

2023-02-13  

N/A  

2023-01  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
: Selective extended dissection (SED) group

PROCEDURE: Selective extended dissection of pancreaticoduodenectomy

  • An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.
: Standard dissection (SD) group

Primary Outcome MeasuresMeasure DescriptionTime Frame
Disease-free survival (DFS)From the day the patient received surgery to the time the patient was diagnosed with postoperative recurrence, assessed up to 36 months.
Secondary Outcome MeasuresMeasure DescriptionTime Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:

Accepts Healthy Volunteers:

    Inclusion Criteria:
    - 1) Patients diagnosed as resectable pancreatic cancer were pathologically diagnosed as PDAC after surgery.
    2) Patients received radical surgery (R0) and had complete photos or videos of the operation.
    Exclusion Criteria:
    - 1) The operation records as well as related photo or video data could not reflect the surgical approach and the extent of resection.
    2) Patients with incomplete clinical, pathological, imaging and follow-up information.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Guo X, Song Y, Xu P, Zhu W, Wang H, Zhou Y, Huang C, Hao J, Gao S. Selective extended dissection for pancreaticoduodenectomy is associated with better survival in pancreatic cancer patients: retrospective cohort study. Int J Surg. 2023 Jul 1;109(7):1852-1862. doi: 10.1097/JS9.0000000000000437.